Our Purpose
The CVR is the largest grouping of scientists dedicated to virological research in the UK and has a global reputation for excellence in research. The goal of CRUSH is to extend and translate this expertise to the wider industrial and academic community, providing a platform where collaborations between industry and academia can flourish. CRUSH can provide unrivalled insight, while our implementation of state-of-the-art technologies enables us to offer value to clients.
CRUSH is a fully integrated hub with access to bespoke biocontainment facilities and the expertise to support small animal model studies of high consequence viruses, including SARS-CoV-2. Proximity to the CVR’s virology expertise, viral genomics and computational biology capabilities further strengthens the CRUSH offering.
We can draw from the individual expertise of academic scientists in the CVR, ensuring we provide the highest possible level of scientific excellence. We always aim to translate and integrate project outputs and learnings into our clients and partner organisations, ensuring we provide not only a high quality research service, but scientific understanding and access to the decision-making process for our clients & partners.
CRUSH has the facilities and expertise to advise and deliver projects from pilot studies through to small animal model efficacy studies. We strive to deliver value, while never compromising on scientific excellence.
Our Services
-
Compound Screening
Our pipelines provide in vitro assays to screen and assess novel and existing compounds for their antiviral potential (or activity) against viruses, including new and emerging pathogens.
-
Small Animal Models
We currently provide in vivo antiviral drug efficacy evaluation studies in mouse and Syrian hamster models, with plans to acquire further preclinical models to provide the broadest possible range of preclinical services.
-
Combination, Kinetic and Resistance Assays
Our team can provide an in-depth assessment of drug resistance acquisition in high-consequence viruses.
-
Rescue and Genetic Modification of Viruses
We use modern reverse genetics and related recombinant technologies to recover and generate wild-type and genetically modified infectious viruses.
-
Custom Services
With access to our state-of-the-art facilities and scientific expertise, we have the capability to find solutions for your specific project needs.
“Whilst CRUSH activities will initially focus on the COVID-19 pandemic, the CVR and the CRUSH facility are well positioned to rapidly respond to future viral outbreaks, delivering innovation to address public health crises caused by high consequence viruses. We look forward to working with academic and industry partners to develop CRUSH as a national facility.”
— Massimo Palmarini, CVR Director